Why the study?
Hemoconcentration has been suggested as a biomarker for optimal diuretic therapy in acute heart failure, but its role in rehospitalization and death remained controversial.
Does hemoconcentration during hospitalization predict readmission and mortality in patients with acute heart failure?
Does hemoconcentration during hospitalization predict readmission and mortality in patients with acute heart failure?
Hemoconcentration during hospitalization for acute heart failure may be marginally associated with reduced 6-month mortality, suggesting potential utility as a biomarker for risk stratification.
HC may marginally associate with lower 6-month mortality in acute HF; leaves open its utility for guiding diuretics or predicting readmission.
Background: Hemoconcentration (HC) has been suggested to be a useful biomarker for determination of optimum diuretic therapy in acute heart failure (HF), but role of this factor in rehospitalization and death was still controversial. In this study, we aimed to define relation between HC and readmission and mortality rate among Iranian patients with acute HF. Methods: This was a prospective cohort study done from March 2017 to March 2018 using data of a HF section of Persian Registry Of cardioVascular diseasE. From a total number of 390 registered HF individuals aged 18 years or older, 69 ones showed alterations in hemoglobin (Hb) levels. Hb levels were measured at admission and discharge time. HC was defined as any increased level in Hb during hospitalization. The relation of HC with readmission and death rate was done using multiple logistic regression and Cox proportional hazard model, respectively. Results: The mean age of study population was 70.5 ± 11.9 years with the dominant percentage of male participants (66.9%). Patients showing HC during admission did not reveal any significant decreased likelihood of rehospitalization compared to negative ones. In comparison to HC negative patients, those showing increments in Hb levels had a borderline significant lower likelihood of mortality (hazard ratio: 0.82, 95% confidence interval, CI = 0.07–1.18, P = 0.08). Conclusions: Our data suggested that HC was associated marginally with reduced mortality rate 6 months post HF attack and could be utilized as a useful biomarker for risk stratification of HF patients. Several prospective longitudinal population-based studies are necessary proving these associations.
No takes yet. Share an insight, caveat, or question.
Farsani et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: